GlassScriptPhysician profile
Dhaval Raval
NPI 1528214947
$2,830.60
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $365 · 2021: $1,163 · 2023: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,483.08 | 2019-2021 | |
| Glaxosmithkline, LLC. | $292.50 | 2019-2020 | |
| Genentech USA, INC. | $226.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.11 | 2019 | |
| Pfizer INC. | $153.76 | 2019-2020 | |
| Philips North America LLC | $120.65 | 2019-2020 | |
| Abbott Laboratories | $106.66 | 2023 | Mitraclip |
| Grifols USA, LLC | $50.82 | 2020 | |
| Insmed, INC. | $42.38 | 2019 | |
| Electromed, INC. | $34.77 | 2019 | |
| Astellas Pharma US INC | $33.23 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.03 | 2019 | |
| Circassia INC. | $17.54 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.64 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $16.03 | 2020 | |
| Shire North American Group INC | $15.81 | 2019 | |
| Merck Sharp & Dohme LLC | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhaval Raval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.